Search Bar & Filters
Found 12 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the effects of two different doses of CHF10067 zampilimab in adults aged 40 years and older who have idiopathic pulmonary fibrosis IPF. This phase IIb study is randomized, double-blind, and placebo-controlled, conducted at multiple centers worldwide. The aim is to assess how well these doses work, how safe they are, and how well participants tolerate them after 24 weeks of treatment. Participants will be randomly assigned to receive one of two doses of CHF10067 or a placebo. The study treatments are given through intravenous infusion. The trial includes three groups running in parallel. The main treatment period lasts for 24 weeks, during which participants receive the assigned infusions and are monitored closely. During the study, participants will undergo various assessments including lung function tests measuring forced vital capacity FVC at multiple time points up to 30 weeks. Researchers will also measure the concentration of CHF10067 in the blood and evaluate participants quality of life related to pulmonary fibrosis symptoms. Safety and tolerability are monitored throughout the study. The total participation duration covers treatment and follow-up visits until at least Week 30.
Actively Recruiting
Researchers are evaluating the effects of AZD6793 in adults with moderate to very severe chronic obstructive pulmonary disease COPD. This Phase IIb study compares two different doses of AZD6793 to placebo tablets to assess their efficacy and safety. The study is randomized, double-blind, placebo-controlled, and involves about 970 participants worldwide. Participants will be randomly assigned to one of three groups two different doses of AZD6793 or a matching placebo. The study lasts for 24 weeks, during which participants will take oral tablets of their assigned treatment. The trial aims to measure how well AZD6793 works to reduce COPD exacerbations compared to placebo. Throughout the study, participants will have regular assessments including lung function tests, symptom questionnaires, and blood tests to measure drug levels. Researchers will monitor the rate of COPD exacerbations, lung function changes, and symptom scores over 24 weeks. Safety and tolerability of the treatments will also be closely observed during this period.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of tezepelumab in adults with moderate to very severe chronic obstructive pulmonary disease COPD who are already receiving inhaled maintenance therapy and have experienced recent COPD exacerbations. This Phase 3, multicenter, randomized, double-blind, placebo-controlled study aims to understand how tezepelumab impacts COPD outcomes compared to a placebo. Participants will receive monthly subcutaneous injections of one of two doses of tezepelumab or a matching placebo. The treatment period lasts a minimum of 52 weeks and up to 76 weeks. Following treatment, there is a 12-week safety follow-up without active treatment to monitor participants. Throughout the study, participants will be monitored regularly to assess lung function, COPD symptoms, and exacerbation rates. Researchers will collect data on lung function tests, symptom questionnaires, and exacerbation frequency up to 76 weeks. Blood samples will be taken to study drug levels and immune responses. The total participation time for each individual includes the treatment period plus the safety follow-up phase.
Actively Recruiting
This research aims to evaluate the long-term safety and tolerability of inhaled antifibrotic medications, specifically AP01, in participants who have previously completed Avalyn Pharma sponsored studies involving this treatment. The study focuses on individuals with progressive pulmonary fibrosis or idiopathic pulmonary fibrosis IPF, excluding IPF subjects from the US and Canada. The goal is to continue assessing the effects of AP01 over an extended period. Participants will receive 100 mg of inhaled pirfenidone solution AP01 twice daily using the eFlow Nebulizer System. The study includes a ScreeningBaseline Visit, an open-label Treatment Period where all participants receive AP01, and a Follow-upEnd of Study phone call approximately two weeks after the last dose. The dosing during the treatment period will be monitored with a paper diary and by collecting any unused medication. Throughout the study, participants will be assessed for long-term safety and tolerability outcomes, including changes in lung function measured by forced vital capacity FVC, disease stabilization, and quality of life. The trial is expected to last an average of six years, with evaluations continuing until the studys end. Participants will have regular monitoring and follow-up to track their progress and adherence to the treatment.
Actively Recruiting
Researchers are evaluating the efficacy and safety of trimodulin as an additional treatment to the standard care for hospitalized adult patients with severe community-acquired pneumonia sCAP who require invasive mechanical ventilation IMV. This phase III, randomized, placebo-controlled, and double-blind trial aims to compare trimodulin plus standard care against placebo plus standard care. The study also includes assessments of trimodulins detailed pharmacokinetic and pharmacodynamic properties. Participants are randomly assigned in a 11 ratio to receive either trimodulin or a placebo, both given intravenously once daily for five consecutive days alongside standard care. Following treatment, participants enter a follow-up phase lasting up to 23 days, with an end-of-follow-up visit or phone call on day 29. For those still hospitalized after day 29, extended follow-up continues until discharge or day 90, and a closing visit or call is conducted around day 91. During the study, participants will undergo multiple assessments including evaluation of mortality rates up to 28 and 90 days, clinical cure rates, organ failure scores, ventilator use, oxygen supply, ICU and hospital stays, readmission rates, adverse events, and changes in vital signs and laboratory parameters. Safety monitoring includes electrocardiograms and tracking of adverse events throughout the treatment and follow-up periods. The total participation duration can extend up to approximately three months depending on hospital discharge timing.
Actively Recruiting
Researchers are evaluating the efficacy, safety, and tolerability of subcutaneous treatment with lunsekimig compared with placebo in adults aged 40 to 80 years who have inadequately controlled Chronic Obstructive Pulmonary Disease COPD characterized by an eosinophilic phenotype. This Phase 2bPhase 3 study includes participants with a history of COPD, ongoing symptoms despite treatment, and specific lung function and blood eosinophil criteria. Participants will be randomly assigned to one of three groups lunsekimig dose regimen A, lunsekimig dose regimen B, or a placebo group. All treatments are given as subcutaneous injections during a 48-week treatment period. The study consists of a screening period up to 4 weeks, followed by the 48-week randomized treatment, and then an approximately 8-week follow-up period, totaling up to 60 weeks of participation. During the study, participants will undergo lung function tests, symptom and quality of life questionnaires, and blood tests to monitor eosinophil counts and drug levels. The main outcome measured is the annualized rate of moderate-to-severe COPD exacerbations over 48 weeks. Additional assessments include changes in lung function, symptom scores, safety events, and antibody development. Safety monitoring continues through the follow-up period after treatment ends.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of Nalbuphine Extended-Release NAL ER tablets in treating chronic cough in people with Idiopathic Pulmonary Fibrosis IPF. This phase 3 study aims to understand how NAL ER affects cough frequency and severity compared to a placebo. The study is led by Trevi Therapeutics and focuses on participants aged 40 and older who have persistent cough due to IPF. Participants will be randomly assigned to one of two groups. One group will take NAL ER tablets while the other receives matching placebo tablets. There will be a 2-week blinded titration period with once daily dosing followed by a 52-week fixed dose period with twice daily dosing. This design helps compare the effects of NAL ER versus placebo over a year-long treatment. During the trial, participants will be monitored regularly to track changes in cough frequency and severity using several scales and questionnaires, including the Cough Severity Numerical Rating Scale and the Leicester Cough Questionnaire. Safety and tolerability will also be assessed by recording adverse events. The main outcome measure is the relative change in 24-hour cough frequency after 26 weeks of treatment, with additional assessments continuing through 54 weeks. The total study duration for each participant is about one year.
Actively Recruiting
Researchers are evaluating the use of an ECG-based artificial intelligence device to help predict if people with interstitial lung disease ILD are at high risk for undiagnosed pulmonary hypertension PH. The study aims to see whether using this device increases the number of new PH diagnoses over six months compared to standard care. This multi-center randomized trial focuses on adults diagnosed with ILD and assesses how well the AI device performs in clinical practice. Participants with ILD will each receive a 12-lead electrocardiogram ECG that the AI device analyzes to identify those at high risk for PH. Participants will be randomly assigned to either receive the device results or not. Those in the device group identified as high risk will undergo additional tests including an echocardiogram and right heart catheterization RHC. Other participants will continue with their usual care, which may include those tests if their doctor recommends them. During the study, participants will be followed for approximately six months to monitor new diagnoses of pulmonary hypertension. The research team will review how many participants receive new PH diagnoses in the different groups. Standard clinical care will continue throughout, and participants will have relevant heart and lung assessments as needed. The study will help determine if the AI device improves detection of pulmonary hypertension in people with ILD.
Actively Recruiting
Researchers are evaluating the efficacy and safety of recombinant human plasma gelsolin rhu-pGSN combined with standard care in adults with moderate-to-severe Acute Respiratory Distress Syndrome ARDS caused by pneumonia or other infections. This Phase 2, randomized, double-blind, placebo-controlled study aims to enroll patients hospitalized within 24 hours of ARDS diagnosis, focusing on those with a low oxygenation ratio PF ratio 4150 requiring mechanical or noninvasive ventilation or high-flow oxygen support. Participants are randomly assigned to receive either rhu-pGSN or a matching saline placebo alongside standard care. The treatment involves a single loading dose of rhu-pGSN at 24 mgkg, followed by five daily doses of 12 mgkg administered intravenously through a filtered syringe. Patients receive the study drug within 48 hours of ARDS diagnosis. The study includes assessments such as blood tests, imaging, cultures, and antibody measurements at baseline and specified times. Safety reviews are conducted periodically by an independent monitoring board. Throughout the study, participants undergo detailed evaluations including medical history, infection site identification, physical exams, chest imaging, blood and sputum cultures, and laboratory tests for inflammatory markers. Follow-up occurs on Days 7, 14, 28, and 60 to assess mortality and respiratory support outcomes. Safety monitoring includes serious adverse event reviews. The total participation duration extends through at least 60 days following treatment to evaluate all-cause mortality and other clinical outcomes.
Actively Recruiting
Idiopathic Pulmonary Fibrosis IPF is a rare, chronic lung disease that causes scarring of lung tissue, resulting in shortness of breath and reduced lung function. This platform study evaluates various treatments for IPF, including the investigational drug ABBV-142. The study aims to assess the safety, tolerability, and effectiveness of these treatments in adults with IPF using a master protocol that allows adding or closing substudies over time. Participants will be randomly assigned to receive either ABBV-142 or a matching placebo in a double-blind manner for 52 weeks during the initial treatment phase. Those who qualify may then receive ABBV-142 for an additional 52 weeks in an open-label extension. This design helps compare the investigational drug with placebo and further monitors participants over an extended period. Throughout the study, participants will attend regular visits at hospitals or clinics where medical assessments, blood tests, side effect monitoring, and questionnaires will be conducted. Researchers will measure lung function changes, adverse events, and quality of life impacts. After treatment, participants will be followed for 120 days to monitor their health and study outcomes.
1-10 of 12
1